New SBIR Funding Announced

Syntermed has received another NIH award for a Phase II SBIR grant titled "Myocardial blood flow quantitation with the novel PET F-18 Flurpiridaz imaging tracer." Award number R44HL123069. The funding period is 3/1/16-2/28/18. The product developed from this grant will improve the field of nuclear cardiology by offering optimized relative and absolute quantitation of myocardial perfusion and blood flow for the F-18 flurpiridaz agent.


Archive
Search By Tags
No tags yet.